Global Virtual Congress
VIRO 2026 – Global Voices in Renal Oncology
Overview
Event Highlights
- Bridge emerging evidence and real-world practice across the full RCC spectrum
- Solve practical challenges: first-line selection, sequencing, toxicity management
- Make renal cancer care more global and equitable
Event Series
Date / Time
Sep 10, 2026 – Sep 11, 2026
Save to
VIRO 2026 – Global Voices in Renal Oncology is a global virtual medical congress dedicated to renal oncology, renal cell carcinoma, and the evolving management of kidney cancer in 2026. The Congress brings together leading international experts to discuss current standards of care, emerging treatment strategies, multidisciplinary decision-making, and practical approaches to improving outcomes for patients with renal malignancies.
The OncoDaily VIRO 2026 Congress will focus on the changing landscape of renal cancer care, with a strong emphasis on translating clinical evidence into real-world practice. As renal oncology continues to evolve, clinicians are increasingly faced with complex decisions involving treatment selection, sequencing, toxicity management, biomarkers, and access to innovation across different healthcare systems.
Renal cell carcinoma accounts for approximately 430,000 new cases and 155,000–180,000 deaths worldwide each year, based on global cancer estimates. While outcomes are favorable for localized disease in high-resource settings, survival declines substantially in advanced stages, particularly in metastatic disease. Despite earlier detection in some regions, a significant proportion of patients still develop advanced disease, where durable control remains challenging.
In recent years, the therapeutic landscape of renal cancer has changed rapidly. The integration of immune checkpoint inhibitors, VEGF-targeted therapies, and combination regimens has reshaped standards of care for advanced and metastatic renal cell carcinoma. These advances have improved outcomes for many patients, yet they also introduce new challenges related to optimal patient selection, sequencing after progression, long-term toxicity management, and the adaptation of evidence-based strategies to diverse clinical environments.
Speakers
Speakers VIRO 2026
Scientific Program
The scientific program of VIRO 2026 – Global Voices in Renal Oncology will explore the full clinical spectrum of renal cell carcinoma, from localized and high-risk disease to advanced and metastatic renal cancer. Sessions will address contemporary approaches to diagnosis, risk assessment, systemic therapy, multidisciplinary care, and follow-up, while highlighting how evolving clinical evidence can be applied in daily practice.
Expert-led discussions will examine the role of immunotherapy-based combinations, VEGF-targeted treatment strategies, adjuvant approaches, management after disease progression, and the future of biomarker-informed decision-making. The congress will also focus on key practical questions in renal oncology, including how to select the most appropriate first-line regimen, how to manage immune-related and treatment-related adverse events, and how to personalize care based on disease biology, patient characteristics, and available resources.
VIRO 2026 also recognizes that progress in renal cancer care must be global. Access to advanced diagnostics, clinical trials, systemic therapies, multidisciplinary expertise, and supportive care remains uneven across regions. By bringing together voices from different countries and healthcare systems, the congress aims to foster international dialogue on how innovation can be delivered more equitably and effectively.
Designed for medical oncologists, urologists, radiation oncologists, surgeons, pathologists, radiologists, researchers, trainees, nurses, and other professionals involved in renal cancer care, VIRO 2026 will provide a practical and forward-looking platform for education, collaboration, and clinical exchange.
VIRO 2026 – Global Voices in Renal Oncology aims to support more personalized, effective, and equitable care for patients with renal malignancies worldwide. Through global expertise, multidisciplinary discussion, and real-world perspectives, the congress will help bridge the gap between emerging evidence and everyday clinical practice in renal oncology.
Chairs
Pedro Barata is Associate Professor of Medicine at Case Western Reserve University School of Medicine and a medical oncologist at University Hospitals Seidman Cancer Center. He specializes in genitourinary cancers, including kidney, bladder, and prostate cancer. An internationally recognized researcher and speaker, Dr. Barata has expertise in immunotherapy, targeted therapies, precision oncology, and clinical trial development, contributing to advances in evidence-based and multidisciplinary cancer care.
Enrique Grande is Director of the Medical Oncology Program and Clinical Research Lead at MD Anderson Cancer Center Madrid. An internationally recognized medical oncologist, he specializes in genitourinary cancers and neuroendocrine tumors, with research focused on clinical trials, targeted therapies, and precision oncology. He has played a leading role in advancing innovative treatment strategies and improving outcomes for patients with complex malignancies.
Speakers
Speakers VIRO 2026
Scientific Program
The scientific program of VIRO 2026 – Global Voices in Renal Oncology will explore the full clinical spectrum of renal cell carcinoma, from localized and high-risk disease to advanced and metastatic renal cancer. Sessions will address contemporary approaches to diagnosis, risk assessment, systemic therapy, multidisciplinary care, and follow-up, while highlighting how evolving clinical evidence can be applied in daily practice.
Expert-led discussions will examine the role of immunotherapy-based combinations, VEGF-targeted treatment strategies, adjuvant approaches, management after disease progression, and the future of biomarker-informed decision-making. The congress will also focus on key practical questions in renal oncology, including how to select the most appropriate first-line regimen, how to manage immune-related and treatment-related adverse events, and how to personalize care based on disease biology, patient characteristics, and available resources.
VIRO 2026 also recognizes that progress in renal cancer care must be global. Access to advanced diagnostics, clinical trials, systemic therapies, multidisciplinary expertise, and supportive care remains uneven across regions. By bringing together voices from different countries and healthcare systems, the congress aims to foster international dialogue on how innovation can be delivered more equitably and effectively.
Designed for medical oncologists, urologists, radiation oncologists, surgeons, pathologists, radiologists, researchers, trainees, nurses, and other professionals involved in renal cancer care, VIRO 2026 will provide a practical and forward-looking platform for education, collaboration, and clinical exchange.
VIRO 2026 – Global Voices in Renal Oncology aims to support more personalized, effective, and equitable care for patients with renal malignancies worldwide. Through global expertise, multidisciplinary discussion, and real-world perspectives, the congress will help bridge the gap between emerging evidence and everyday clinical practice in renal oncology.
Partnership Opportunities
Partnership & Collaboration Opportunities
Shushan Hovsepyan
Senior Vice President, OncoDaily
Email: [email protected]
Phone: +1 571 775 9710
Event-Related Inquiries
Inessa Mkhitaryan
Head of Global Events, OncoDaily
Email: [email protected]
General Inquiries
Email: [email protected]
